Alkermes (ALKS) Non-Current Deffered Revenue (2011 - 2022)
Alkermes (ALKS) posted quarterly Non-Current Deffered Revenue of $6.4 million for Q3 2022, down 50.25% year-over-year from $12.9 million in Q3 2021, and down 44.3% quarter-over-quarter from $11.5 million in Q4 2021.
Alkermes (ALKS) Non-Current Deffered Revenue (2011 - 2022) Analysis & Trends
Alkermes (ALKS) has reported Non-Current Deffered Revenue for 12 consecutive years, with $6.4 million the latest figure, recorded in Q3 2022.
- In Q3 2022, Non-Current Deffered Revenue fell 50.25% year-over-year to $6.4 million; the TTM figure through Sep 2022 stood at $6.4 million (down 50.25% YoY), while the FY2021 annual figure was $11.5 million, down 29.92% from the prior year.
- Non-Current Deffered Revenue eased to $6.4 million in Q3 2022 per ALKS's latest filing, from $11.5 million in the prior quarter.
- Across five years, Non-Current Deffered Revenue topped out at $22.1 million in Q4 2019 and bottomed at $5.0 million in Q3 2018.
- Historically, Non-Current Deffered Revenue has averaged $12.8 million across 5 years, with a median of $11.6 million in 2019.
- Annual changes were most pronounced in 2019 — Non-Current Deffered Revenue jumped 131.69% — and 2022, when it tumbled 50.25%.
- Alkermes' Non-Current Deffered Revenue stood at $9.5 million in 2018, then surged by 131.69% to $22.1 million in 2019, then slipped by 25.7% to $16.4 million in 2020, then dropped by 29.92% to $11.5 million in 2021, then tumbled by 44.3% to $6.4 million in 2022.
- Business Quant data shows ALKS's Non-Current Deffered Revenue at $6.4 million in Q3 2022, $11.5 million in Q4 2021, and $12.9 million in Q3 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.07 Bn | 43.11 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.27 Bn | 39.62 Bn | 2.15 Bn | - |
| 3 | Zoetis | 31.99 Bn | 30.31 Bn | 1.05 Bn | - |
| 4 | Takeda Pharmaceutical | 28.78 Bn | 22.99 Bn | 5.10 Bn | - |
| 5 | United Therapeutics | 22.26 Bn | 19.60 Bn | 683.80 Mn | - |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | - |
| 7 | Neurocrine Biosciences | 15.58 Bn | 15.19 Bn | 935.80 Mn | - |
| 8 | Elanco Animal Health | 11.93 Bn | 11.40 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | - |
| 10 | Alkermes | 8.15 Bn | 7.49 Bn | 397.90 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2022 | 6.40 Mn |
| Dec 31, 2021 | 11.49 Mn |
| Sep 30, 2021 | 12.86 Mn |
| Jun 30, 2021 | 14.17 Mn |
| Mar 31, 2021 | 14.75 Mn |
| Dec 31, 2020 | 16.40 Mn |
| Sep 30, 2020 | 18.64 Mn |
| Jun 30, 2020 | 18.88 Mn |
| Mar 31, 2020 | 21.16 Mn |
| Dec 31, 2019 | 22.07 Mn |
| Sep 30, 2019 | 11.19 Mn |
| Jun 30, 2019 | 11.62 Mn |
| Mar 31, 2019 | 11.34 Mn |
| Dec 31, 2018 | 9.53 Mn |
| Sep 30, 2018 | 5.01 Mn |
| Jun 30, 2018 | 5.86 Mn |
| Mar 31, 2018 | 6.17 Mn |
| Dec 31, 2017 | 5.66 Mn |
| Sep 30, 2017 | 6.13 Mn |
| Jun 30, 2017 | 6.78 Mn |